A Phase 3 interventional study of Seltorexant and Matching placebo to Seltorexant in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 175 sites in 15 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.
Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one has the largest enrollment, is one of 4 that started in 2020, is one of 5 in phase 3, and was the 7th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18–74
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 13 more countries
Ages 18–74
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 757 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 176 across the 12 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 3rd largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2020, is one of 23 in phase 3, and was the 37th registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing seltorexant in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing seltorexant in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.
Drug: Seltorexant · Drug: Matching placebo to Seltorexant
Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.
Drug: Quetiapine XR · Drug: Matching placebo to Quetiapine XR
Participants will receive seltorexant over-encapsulated tablet orally.
Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
Participants will receive quetiapine XR capsule orally.
Participants will receive placebo capsule matching to quetiapine XR orally.
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with \>= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.
Time frame: Week 26
Change From Baseline to Week 26 in Weight
Change from baseline to Week 26 in weight was reported.
Time frame: Baseline (Day 1) and Week 26
Time to Potentially Treatment Related Discontinuation of Study Drug
Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used.
Time frame: From first dose of study drug (Day 1) up to Week 30
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.
Time frame: Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in MADRS-6 Total Score
Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition.
Time frame: Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.
Time frame: Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement.
Time frame: Baseline (Day 1) and Week 26
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Percentage of participants with MADRS total score \<=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was \<=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.
Time frame: Week 26
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Percentage of participants with a \>=50 percent improvement in MADRS total score and MADRS \<=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.
Time frame: Week 26
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Percentage of participants with \>=7 percent weight increase from baseline at Week 26 was reported.
Time frame: Week 26
Adult participants aged 18 to 64 years and elderly participants aged 65 to 74 years with major depressive disorder with insomnia symptoms (MDDIS), who had an inadequate response to ongoing antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) were randomized in the study.
| Milestone | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Started | 367 | 390 |
| Treated | 366 | 390 |
| Full analysis set 1 (fas1) | 355 | 371 |
| Completed | 277 | 270 |
| Not completed | 90 | 120 |
| Withdrew: Adverse event | 21 | 44 |
| Withdrew: Lack of efficacy | 5 | 4 |
| Withdrew: Withdrawal by subject | 27 | 46 |
| Withdrew: Lost to follow-up | 9 | 7 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Non-compliance with study drug | 8 | 8 |
| Withdrew: Non-compliance with primary antidepressant | 4 | 2 |
| Withdrew: Initiated prohibited medication | 2 | 0 |
| Withdrew: Other | 7 | 6 |
| Withdrew: Randomized and not treated | 1 | 0 |
| Milestone | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Started | 328 | 344 |
| Completed | 299 | 304 |
| Not completed | 29 | 40 |
| Withdrew: Adverse event | 5 | 10 |
| Withdrew: Withdrawal by subject | 13 | 20 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Other | 10 | 7 |
Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with \>= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.
| percentage of participants | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26 | 57.4 | 53.4 |
Change from baseline to Week 26 in weight was reported.
| Kilograms (Kg) | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Change From Baseline to Week 26 in Weight | 0.5 ± 2.89 | 2.1 ± 3.93 |
Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used.
| days | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Time to Potentially Treatment Related Discontinuation of Study Drug | NA (NA to NA) | 206 (NA to NA) |
Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.
| score on a scale | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -23.0 ± 10.12 | -22.7 ± 9.54 |
Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition.
| score on a scale | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Change From Baseline to Week 26 in MADRS-6 Total Score | -14.8 ± 6.85 | -14.5 ± 6.64 |
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.
| score on a scale | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score | -19.9 ± 9.22 | -19.5 ± 8.64 |
Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement.
| score on a scale | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score | -12.1 ± 6.36 | -12.5 ± 5.95 |
Percentage of participants with MADRS total score \<=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was \<=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.
| percentage of participants | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26 | 46.9 | 43.5 |
Percentage of participants with a \>=50 percent improvement in MADRS total score and MADRS \<=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.
| percentage of participants | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26 | 57.1 | 52.1 |
Percentage of participants with \>=7 percent weight increase from baseline at Week 26 was reported.
| percentage of participants | Seltorexant | Quetiapine Extended-release (XR) |
|---|---|---|
| Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26 | 4.4 | 18.3 |
Collected over DB Phase: From Day 1 up to Week 30, Follow-up Phase: From Week 30 up to Week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind Phase: Seltorexant | 0/366 (0%) | 5/366 (1.4%) | 99/366 (27%) |
| Double Blind Phase: Quetiapine XR | 0/390 (0%) | 6/390 (1.5%) | 200/390 (51.3%) |
| Follow-up Phase : Seltorexant | 0/328 (0%) | 2/328 (0.6%) | 5/328 (1.5%) |
| Follow-up Phase: Quetiapine XR | 0/344 (0%) | 0/344 (0%) | 8/344 (2.3%) |
| Event | Double Blind Phase: Seltorexant | Double Blind Phase: Quetiapine XR | Follow-up Phase : Seltorexant | Follow-up Phase: Quetiapine XR |
|---|---|---|---|---|
| Panic AttackPsychiatric disorders | 0/366 | 0/390 | 1/328 | 0/344 |
| Suicide AttemptPsychiatric disorders | 0/366 | 0/390 | 1/328 | 0/344 |
| Drug-Induced Liver InjuryHepatobiliary disorders | 1/366 | 0/390 | 0/328 | 0/344 |
| Covid-19Infections and infestations | 1/366 | 0/390 | 0/328 | 0/344 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/366 | 0/390 | 0/328 | 0/344 |
| DepressionPsychiatric disorders | 1/366 | 0/390 | 0/328 | 0/344 |
| Cervical DysplasiaReproductive system and breast disorders | 1/366 | 0/390 | 0/328 | 0/344 |
| AnaemiaBlood and lymphatic system disorders | 0/366 | 1/390 | 0/328 | 0/344 |
| PalpitationsCardiac disorders | 0/366 | 1/390 | 0/328 | 0/344 |
| Haemorrhoidal HaemorrhageGastrointestinal disorders | 0/366 | 1/390 | 0/328 | 0/344 |
| Event | Double Blind Phase: Seltorexant | Double Blind Phase: Quetiapine XR | Follow-up Phase : Seltorexant | Follow-up Phase: Quetiapine XR |
|---|---|---|---|---|
| SomnolenceNervous system disorders | 23/366 | 94/390 | 0/328 | 0/344 |
| Weight IncreasedInvestigations | 20/366 | 54/390 | 1/328 | 2/344 |
| HeadacheNervous system disorders | 42/366 | 43/390 | 3/328 | 5/344 |
| Dry MouthGastrointestinal disorders | 10/366 | 38/390 | 0/328 | 0/344 |
| FatigueGeneral disorders | 13/366 | 23/390 | 0/328 | 2/344 |
| NauseaGastrointestinal disorders | 11/366 | 20/390 | 1/328 | 0/344 |
Baseline characteristics are reported for FAS2 analysis set which included all randomized participants who received at least 1 dose of study intervention.
| Age, Categorical(Participants) | Seltorexant | Quetiapine Extended-release (XR) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 337 | 349 | 686 |
| >=65 years | 29 | 41 | 70 |
| Age, Continuous(years) | Seltorexant | Quetiapine Extended-release (XR) | Total |
|---|---|---|---|
| Mean | 47.8 ± 13.15 | 47.9 ± 13.64 | 47.9 ± 13.4 |
| Sex: Female, Male(Participants) | Seltorexant | Quetiapine Extended-release (XR) | Total |
|---|---|---|---|
| Female | 281 | 277 | 558 |
| Male | 85 | 113 | 198 |
| Ethnicity (NIH/OMB)(Participants) | Seltorexant | Quetiapine Extended-release (XR) | Total |
|---|---|---|---|
| Hispanic or Latino | 79 | 83 | 162 |
| Not Hispanic or Latino | 284 | 301 | 585 |
| Unknown or Not Reported | 3 | 6 | 9 |
| Race (NIH/OMB)(Participants) | Seltorexant | Quetiapine Extended-release (XR) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 13 | 13 | 26 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 17 | 21 | 38 |
| White | 327 | 351 | 678 |
| More than one race | 6 | 2 | 8 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Region of Enrollment(Participants) | Seltorexant | Quetiapine Extended-release (XR) | Total |
|---|---|---|---|
| Argentina | 42 | 46 | 88 |
| Belgium | 1 | 2 | 3 |
| Bulgaria | 48 | 47 | 95 |
| Canada | 0 | 1 | 1 |
| Czech Republic | 17 | 16 | 33 |
| Latvia | 8 | 10 | 18 |
| Lithuania | 6 | 9 | 15 |
| Malaysia | 10 | 12 | 22 |
| Poland | 15 | 17 | 32 |
| Russian Federation | 15 | 18 | 33 |
| Serbia | 54 | 57 | 111 |
| Slovakia | 29 | 28 | 57 |
| Ukraine | 10 | 13 | 23 |
| United Kingdom | 1 | 1 | 2 |
| United States | 110 | 113 | 223 |
Showing the first 100 of 175 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Sep 2020 to primary completion in Oct 2023, 36 months.
Results were first posted in Nov 2026, 3 years 1 month after primary completion. A results delay was requested in Oct 2024.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 36 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seltorexant
Janssen Research & Development, LLC →